Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir

Atazanavir/ritonavir concentrations change over pregnancy in HIV-positive patients; the impact of genetic variants is unknown. 20 patients were enrolled: antiretrovirals' plasma and intracellular concentrations were measured in addition to single nucleotide polymorphisms in transport affecting genes. Linear logistic regression showed that genetic variants in organic-anion-transporter-1B1 and pregnane-X-receptor encoding genes affected third trimester atazanavir exposure. In this prospective study genetic variants partially explained the observed inter-patient variability in third-trimester antiretrovirals' exposure.